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ABSTRACT Spontaneous conversion of beta-amyloid peptide (A) from soluble monomer to insoluble fibril may underlie the
neurodegeneration associated with Alzheimer’s disease. A complete description of A self-association kinetics requires
identification of the oligomeric species present and the pathway of association, as well as quantitation of rate constants and
reaction order. A was rendered monomeric and denatured by dissolution in 8 M urea, pH 10. “Refolding” and fibrillization
were initiated by rapid dilution into phosphate-buffered saline, pH 7.4. The kinetics of growth were followed at three different
concentrations, using size exclusion chromatography, dynamic light scattering, and static light scattering. A multi-step
pathway for fibril formation and growth was postulated. This pathway included 1) rapid commitment to either stable
monomer/dimer or unstable intermediate, 2) cooperative association of intermediate into a multimeric “nucleus,” 3) elongation
of the “nucleus” into filaments via addition of intermediate, 4) lateral aggregation of filaments into fibrils, and 5) fibril elongation
via end-to-end association. Differential and algebraic equations describing this kinetic pathway were derived, and model
parameters were determined by fitting the data. The utility of the model for identifying toxic A oligomeric specie(s) is
demonstrated. The model should prove useful for designing compounds that inhibit A aggregation and/or toxicity.
NOMENCLATURE
ctot  Total mass concentration of peptide;
[D]  Molar concentration (in equivalent
monomers) of stable dimer;
d  Filament or fibril diameter;
df  Filament diameter;
dF  Fibril diameter;
dsph  Hydrodynamic diameter of a sphere with
equivalent diffusivity;
Dz  Z-average translational diffusion coefficient;
[fi]  Molar concentration of filaments;
[Fi]  Molar concentration of fibrils;
[I]  Molar concentration (in equivalent
monomers) of amyloidogenic intermediate;
Ib(90°)  Average scattered intensity of buffer at 90°
scattering angle;
Is(90°)  Average scattered intensity of sample at 90°
scattering angle;
Itol  Average scattered intensity of toluene at 90°
scattering angle;
K  Instrument-dependent constant for light
scattering analysis (Eq. 2);
kB  Boltzmann’s constant;
kD  Rate constant, formation of stable dimer from
unfolded monomer;
kI  Rate constant, formation of amyloidogenic
intermediate from unfolded monomer;
kij  Rate constant, fibril elongation by end-to-end
association;
kij  Rate constant, filament elongation by end-to-
end association;
kla  Rate constant, lateral aggregation of filaments
to fibrils;
kM  Rate constant, formation of stable monomer
from unfolded monomer;
KMD  Monomer-dimer equilibrium constant;
kn  Forward rate constant, cooperative association
of intermediate into nucleus;
kn  Reverse rate constant, disassembly of nucleus
into intermediate;
kp  Forward rate constant, addition of
intermediate to nucleus or filament;
kp  Reverse rate constant, dissociation of
intermediate from nucleus or filament;
Lc  Contour length (includes filaments and fibrils);
Lf  Filament length;
LF  Fibril length;
lk  Kuhn statistical segment length;
[M]  Molar concentration of stable monomer;
[Mu]  Molar concentration of urea-unfolded monomer;
M1  Molecular weight of A monomer;
Magg  Wt-averaged molecular weight of all large
aggregates;
Mf  Wt-averaged molecular weight of filaments;
MF  Wt-averaged molecular weight of fibrils;
Mi  Molecular weight of species i;
Mw  Wt-averaged molecular weight (includes all
species);
[N]  Molar concentration of amyloidogenic nucleus;
n  Number of intermediates in nucleus;
nb  Refractive index of buffer;
ntol  Refractive index of toluene;
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NA  Avogadro’s number;
p  Number of filaments in fibril;
P(90°)  Particle scattering factor at 90° scattering angle;
Pf(90°)  Particle scattering factor at 90° scattering
angle for filaments;
PF(90°)  Particle scattering factor at 90° scattering
angle for fibrils;
q  Reaction order, filament to fibril association;
Rtol  Rayleigh ratio for toluene;
T  Temperature;
wagg  Weight fraction peptide in aggregated form;
wf  Weight fraction peptide present as filaments;
wF  Weight fraction peptide present as fibrils;
fib  Maximum allowable distance X angle
between two associating fibrils;
fil  Maximum allowable distance X angle
between two associating filaments;
0  Wavelength of incident light in vacuo;
f  Moment of the filament distribution;
F  Moment of the fibril distribution;
lin  Average linear density of filaments and fibrils;
vh  Partial specific volume of hydrated peptide.
INTRODUCTION
-Amyloid peptide (A) is the major protein component of
senile plaques and cerebrovascular amyloid deposits from
Alzheimer’s disease (AD) patients (Glenner and Wong,
1984; Masters et al., 1985). A is a 39- to 43-residue
proteolytic product of a membrane-associated precursor
protein, APP, containing sequences from both extracellular
and transmembrane regions of the parent protein (Kang et
al., 1987; Masters et al., 1985). The spontaneous conversion
of monomeric A into fibrillar aggregates is associated with
the development of Alzheimer’s disease (Joachim and
Selkoe, 1992). The “amyloid hypothesis,” that A amyloid
deposition is a major causative factor in the onset of AD, is
supported by biochemical, genetic, and transgenic animal
studies (e.g., Yankner et al., 1990; Mattson et al., 1992;
Games et al., 1995; Hsiao et al., 1996; Holcomb et al.,
1998). Similar such conversions of soluble proteins or pro-
tein fragments into fibrillar polymers occur in diseases as
diverse as Huntington’s disease, senile systemic amyloid-
osis, transmissible spongiform encephalitis, and type II di-
abetes (Koo et al., 1999). Proteins unrelated to known
disease states can be induced to form amyloid fibrils by
reducing the conformational stability of the folded globular
protein (Chiti et al., 2000). Indeed, it is possible to generate
libraries of synthetic peptides with the tendency to self-
associate into amyloid; these peptides do not share specific
residue homology, but rather an alternating pattern of
stretches of polar and nonpolar side chains (West et al.,
1999).
Several studies suggest that A is toxic only when it is
aggregated (Pike et al., 1993; Simmons et al., 1994;
Lorenzo and Yankner, 1994; Seilheimer et al., 1997; Hart-
ley et al., 1999; Ward et al., 2000). This apparent link
between the physical state of A and its biological activity
has motivated efforts to understand the kinetics and path-
way of A self-association. Using turbidity to measure
aggregation, Jarrett et al. (1993) proposed a qualitative
kinetic model for A self-association. In this model, mono-
mer is very slowly converted to an n-mer nucleus (lag
phase), followed by rapid addition of monomer to the nu-
cleus to form a fibril (linear phase), until equilibrium is
reached and fibril mass concentration no longer changes
(plateau phase). Tomski and Murphy (1992) used dynamic
light scattering to investigate self-association kinetics of
A(1-40) in phosphate-buffered saline. They hypothesized
that Amonomers spontaneously and completely converted
to octamers, that the octamers stacked to form fibrils, and
that longer fibrils grew by diffusion-limited irreversible
end-to-end association of shorter rodlike fibrils. A quanti-
tative mathematical model was derived to explain the data.
This model accounts for changes in fibril length with time.
However, it assumes complete conversion of monomer to an
oligomer and therefore does not provide a mechanism
whereby monomeric A co-exists with fibrils at equilib-
rium. Furthermore, it neglects monomer addition to the
fibril tip as a mechanism of growth. Naiki and Nakakuki
(1996) used thioflavin T, a dye that fluoresces upon binding
to amyloid fibrils, to measure fibril growth of A(1-40), and
proposed a simple mathematical model to explain their data.
Briefly, fibril elongation was postulated to occur by revers-
ible addition of monomer to preexisting fibrils. This model
is appealing in its simplicity, but does not provide a mech-
anism for generation of new fibrils, nor does it simulate
fibril length. Lomakin et al. (1996, 1997) used dynamic
light scattering to study fibril growth from A(1-40) in 0.1
M HCl and proposed a detailed kinetic model based on
these data. Briefly, rapid reversible equilibration between
monomers and micelles was postulated to occur, followed
by spontaneous and irreversible generation of nuclei from
micelles. Fibrils then grew by addition of monomer to the
nucleus or fibril tip. This work represents the most detailed
mathematical model of A association kinetics published to
date. The model accounts for the presence of both monomer
and fibrillar forms, and can predict both the mass concen-
tration of fibrils and fibril length as a function of time.
However, the experiments upon which the model was based
were conducted at non-physiological conditions (pH  1).
More recent studies have revealed that linear assemblies
of A are not homogeneous in structure or diameter. In
electron microscopy (EM) and atomic force microscopy
(AFM) studies, two types are commonly observed: 3–4-nm
diameter “filaments” (also called protofilaments or protofi-
brils) and 8–10 nm diameter “fibrils” (Stine et al., 1996;
Harper et al., 1997, 1999; Kowalewski and Holtzman, 1999;
Ward et al., 2000). Some investigators have observed small
globular structures that may be the building blocks for
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filaments and fibrils (Stine et al., 1996; Harper et al., 1999).
Malinchik et al. (1998) suggested that fibers are made of
three to five laterally associated filaments, each 3 nm in
diameter. Fraser et al. (1991) observed five to six globular
units with diameters of 2.5–3 nm in EM cross-sections of
amyloid fibers. None of the extant kinetic models specifi-
cally includes both filament and fibril formation and
growth.
In this paper we propose a detailed quantitative model for
the kinetics of conversion of unfolded A into fibrils.
Briefly, A(1-40) was denatured in 8 M urea, then rapidly
diluted into phosphate-buffered saline (PBS) to initiate “re-
folding.” Size exclusion chromatography, dynamic light
scattering, and static light scattering were used to follow the
monomer/oligomer/aggregate distribution and the average
length, diameter, and molecular weight of aggregates as a
function of time. Experiments were repeated at three differ-
ent concentrations, covering a range of kinetic behavior
regimes. The experimental data, together with prior pub-
lished information, were used to develop a detailed kinetic
model that quantitatively describes A self-association ki-
netics from the unfolded state. Parameters were determined
by nonlinear regression fitting of the model to the experi-
mental data. The model incorporated information about
both mass distribution changes and length changes, in-
cluded co-existence of monomer, dimer, and aggregated
species, provided mechanisms for both generation and elon-
gation of fibrils, and explicitly accounted for filaments and
fibrils. The model was able to capture all the essential
features of the experimental data and represents, to our
knowledge, the most detailed and complete quantitative
description of A kinetics at physiological conditions pub-
lished to date. Besides providing a clearer mechanistic un-
derstanding of amyloid fibril growth, such models may
improve our ability to design compounds that modulate
fibril formation, and therefore possess therapeutic potential.
EXPERIMENTAL METHODS
Sample preparation
Urea (electrophysiology/molecular biology grade) was pur-
chased from Boehringer-Mannheim (Indianapolis, IN). All
other chemicals were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise stated. Phosphate-buffered
saline with azide (PBSA; 0.01 M K2HPO4/KH2PO4, 0.14 M
NaCl, 0.02% (w/v) NaN3, pH 7.4) was double-filtered
through 0.22-m filters (Millex); 8 M urea was prepared in
10 mM glycine-NaOH buffer, pH 10, then filtered through
0.22-m filters. Lyophilized A(1-40) (Anaspec, Inc., San
Jose, CA) was solubilized using pre-filtered 8 M urea, pH
10, at a concentration of 2.8 mM (70 and 140 M final
concentration) or 5.6 mM (280 M final concentration) for
10 min. Samples were then rapidly diluted into filtered
PBSA to 70, 140, or 280 M A (equivalent monomer
concentration). All final solutions were at pH 7.4 and con-
tained 0.4 M urea. (Results were not affected by increasing
the incubation time in 8 M urea to 1 h, data not shown.)
Samples were then filtered through 0.45 M filters directly
into light scattering cuvettes or glass vials for further anal-
ysis. MALDI-mass spectroscopy analysis confirmed that
A was not chemically modified by this procedure.
Size exclusion chromatography
Samples were analyzed with size exclusion chromatography
(SEC) using a Superdex 75 column (Pharmacia, Piscataway,
NJ) on a Pharmacia FPLC system. The mobile phase
(PBSA, pH 7.4, containing 0.4 M urea) flow rate was set at
0.05 ml/min and elution peaks were detected by UV absor-
bance at 280 nm. The column was calibrated using the
following proteins as molecular weight standards: insulin
chain B (3500), ubiquitin (8500), ribonuclease A (13,700),
ovalbumin (43,000), and bovine serum albumin (BSA)
(67,000). To determine the distribution between small spe-
cies that could be resolved on the column (MW 3-70), and
larger species that could not be resolved, samples were
injected without the column in place; this peak area was
used to calculate the total A concentration of each sample.
The column was also calibrated with 8 M urea, pH 10,
(with 150 mM NaCl added to the running buffer to prevent
nonspecific interactions with the column), using urea-dena-
tured insulin chain B and ubiquitin as molecular weight
markers. Mobile phase flow rate was varied from 0.05 to 0.1
ml/min. Samples of A in 8 M urea, pH 10, were injected
with and without the column. Apparent molecular weight
was determined by comparison to the calibration data col-
lected in the appropriate buffer, and total recovery was
calculated by comparing peak areas of samples injected
with and without the column in place.
Light scattering
Static and dynamic light scattering data were collected and
analyzed as described previously (Shen et al., 1994).
Briefly, samples in light scattering cuvettes (Hellma, NY)
were placed in a temperature-controlled vat containing
decahydronaphthalene. A Lexel (Fremont, CA) model 95
ion laser operated at 488 nm was focused on the cuvette and
data were collected using a Malvern 4700c system (South-
borough, MA). Dynamic light scattering measurements
were collected at 90° scattering angle hourly or more fre-
quently. Data were analyzed using the method of cumulants
to yield a z-average translational diffusion coefficient Dz.
For the purpose of reporting the data, Dz was converted to
the hydrodynamic diameter of a sphere with equivalent
translational diffusion coefficient, dsph, using the Stokes-
Einstein relationship. Average scattered intensity data at 90°
scattering angle, Is(90°), were collected at the same time
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intervals. For each data point intensity was measured for
10 s, and then averaged. Toluene was used as a standard
reference (Rtol 39.6 104 m1), and the buffer intensity
was also measured.
Bis-ANS fluorescence
A samples were prepared as described above. Aliquots
were removed at specific time intervals, then diluted into
PBS, pH 7.4, such that final samples contained 2 M A,
20 M 1,1-bis(anilino)naphthaline-5,5-disulfonic acid (bis-
ANS) (Molecular Probes, Eugene, OR), and 1 mM urea.
Samples were incubated at room temperature in the dark for
4 min, then analyzed for bis-ANS fluorescence intensity.
Samples were excited at 360 nm, and emission spectra were
taken at 450–550 nm using a PTI spectrofluorometer (South
Brunswick, NJ). A background spectrum of control samples
containing 20 M bis-ANS and 1 mM urea was subtracted
from each sample emission spectrum.
Cellular toxicity
Toxicity of A was assessed as described in detail previ-
ously (Pallitto et al., 1999). Briefly, PC-12 cells were plated
in 96-well polylysine-coated plates with 15,000 cells/100
L medium/well. Lyophilized A was dissolved in pre-
filtered 8 M urea, pH 10, at 12 mg/ml for 10 min, then
diluted to 70, 140, or 280 M with sterile-filtered PBS. The
samples were allowed to aggregate for 1 or 3 days at 25°C,
then diluted to 35 M with fresh media and added to plated
cells. Plates were incubated for 24 h at 37°C, then toxicity
was assessed using the 3-(4-,5 dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide (MTT) assay. All final solu-
tions (including controls) contained 0.4 M urea.
EXPERIMENTAL RESULTS
Unfolding of A in urea
To create a mathematical model of the kinetics of A
aggregation, we needed a well-characterized and reproduc-
ible initial condition. The initial state of synthetic A is
poorly defined; the method of synthesis, the lyophilization
conditions, and the solvent used to dissolve the peptide all
influence the starting conformation and aggregation state
(Barrow et al., 1992; Shen and Murphy, 1995; Thunecke et
al., 1998). For our studies, the preferred state was com-
pletely monomeric and unfolded. We chose 8 M urea, pH
10, as a starting solvent because 8 M urea usually unfolds
polypeptides to the random coil state (Creighton, 1994), and
because A aggregation is hindered at pH 	 9 (Burdick et
al., 1992). Furthermore, refolding of proteins from the urea-
denatured state is a widely used technique in protein-refold-
ing kinetic studies (Goldberg et al., 1991; Fink, 1998).
A(1-40) in 8 M urea, pH 10, eluted as a single sharp
symmetric peak on a calibrated size exclusion column with
a residence time equivalent to 5.3-6.6 kDa (compared to its
known molecular weight of 4.3). The apparent molecular
weight was sensitive to the mobile phase flow rate, decreas-
ing with increasing flow rate. This sensitivity to flow rate is
likely due to the presence of NaCl in the mobile phase, but
not in the sample; NaCl facilitates aggregation of A (data
not shown) but reduces nonspecific interactions with the
column. Recovery of injected A in the monomer peak was
complete within experimental error: at a concentration of
120 M, 99 
 4% (SEM) was recovered, and at 2.8 mM,
97 
 4% was recovered. The intensity of scattered light
from A(1-40) in 8 M urea, pH 10, was not greater than
solvent alone, and there was no change in scattered intensity
over a 24-h period, further indicating the absence of aggre-
gate. Circular dichroic spectra contained no strong bands,
and in particular lacked any trace of a minima at 218 nm or
222 nm, consistent with a lack of -sheet or -helix; how-
ever, the strong absorbance of urea precluded collection of
reliable spectral data below 210 nm, and therefore more
definitive secondary structure assignments could not be
made. Together, these data indicate that 8 M urea, pH 10, is
an effective solvent, and renders A completely monomeric
and unfolded.
A monomer/oligomer size distribution in PBSA
Refolding was initiated by rapid dilution of urea-denatured
A(1-40) into PBSA. The resulting solution was analyzed
with size exclusion liquid chromatography (SEC). Repre-
sentative chromatograms are shown in Fig. 1. Invariably,
two peaks were observed in the inclusion volume of the
column, eluting with retention times corresponding to mo-
lecular masses of 4.1
 0.2 and 9.5
 0.2 kDa. These peaks
will be referred to as monomer and dimer, respectively. A
peak that eluted at the void volume was observed, but not
consistently. No difference in chromatograms was observed
when the sample was centrifuged before injection (data not
shown).
The identical samples were injected using the same sam-
ple loop and detector, but without the column in place, to
measure the total concentration (total peak area) of A. To
calculate the fraction of A in monomer and dimer popu-
lations, the individual peak areas (obtained with the column
in place) were divided by the peak area without the column.
The fraction of aggregates (	70 kDa) was calculated by
difference. A summary of the concentrations of monomer,
dimer, and aggregates is given in Table 1. These values did
not change appreciably over time, up until precipitates were
visible (data not shown). A weighted nonlinear regression
fit to the data yields a relationship between monomer and
dimer of [D]  0.6 
 0.3[M]2
0.2. The second-order de-
pendence on concentration is consistent with assignment of
the two peaks as monomer and dimer.
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A aggregate growth kinetics
Dilution of urea-denatured A into PBSA produced aggre-
gates possessing a linear stiff or semiflexible morphology
(Murphy and Pallitto, 2000). We examined changes in size
of A aggregates as a function of time and concentration.
Aggregate size was characterized by measuring Dz and
converting this to the average hydrodynamic diameter dsph,
which is sensitive to the average length of the aggregates.
(Scattering from monomer/dimer populations is too weak to
be detected in the presence of aggregates.) These data were
previously reported (Murphy and Pallitto, 2000) and are
shown in Fig. 2. Within a few minutes of dilution of
urea-denatured A into PBSA, large aggregates were al-
ready present. Interestingly, aggregates were initially largest
at the lowest concentration (70 M A). Patterns of growth
were strongly concentration-dependent. At 70 M, dsph was
nearly constant. At 140 and 280 M, initial sizes were about
the same (dsph  25 nm); both increased, but the rate of
increase was much faster at 280 M.
Average scattering intensity at 90° scattering angle,
Is(90°), was measured at the same time intervals. Is(90°) is
sensitive to the average molecular weight of the aggregates.
Both the absolute intensity and the rate of change were
dramatically dependent on A concentration (Fig. 3). At 70
M, Is(90°) was relatively constant with time. At 140 M,
Is(90°) slowly doubled over the course of 24 hours. At 280
M, Is(90°) increased6-fold over10 h, then leveled off.
Is(90°) is related to the size and shape of the particles in
solution as (Shen et al., 1994):
Is90	 KctotMwP90
 Ib90 (1)
FIGURE 1 Representative chromatograms of A in PBSA. Lyophilized
A was dissolved in 8 M urea, pH 10, diluted at least 20-fold into PBSA,
then injected onto a Superdex 75 column. Running buffer was PBSA with
0.4 M urea; flow rate was 0.05 ml/min. Peak detection was by absorbance
at 280 nm. Arrows indicate predicted retention times for monomer and
dimer, based on column calibration.
FIGURE 2 Average hydrodynamic diameter (dsph) as a function of time
and concentration for 70 M (E), 140 M (), and 280 M (‚) A
(nominal concentration, equivalent monomers). A was prepared as de-
scribed above; autocorrelation functions were collected at 90° scattering
angle and analyzed as described in the text.
FIGURE 3 Average scattering intensity Is(90°) for 70 M (E), 140 M
(), and 280 M (‚) A. Samples are identical to those described in Fig. 2.
TABLE 1 Size distribution as function of total
A concentration
Nominal
Concentration*
(M)
Measured
Concentration
(M)
Monomer
(M)
Dimer
(M)
Aggregate
(M)
70 60 
 2 7 
 1 33 
 3 20 
 4
140 123 
 7 11 
 2 67 
 8 46 
 9
280 260 
 20 13.6
 0.3 130 
 10 120 
 10
*All concentrations are given in equivalent monomer concentration. The
nominal concentration was calculated based on weighing out a specified
amount of lyophilized peptide. The measured concentration was deter-
mined from the peak area of the sample injected onto the FPLC system
without the column in place, using an extinction coefficient of 0.3062
(mg/ml)1 cm1 (Simmons et al., 1994).
Model of Amyloid Kinetics 1809
Biophysical Journal 81(3) 1805–1822
where ctot total peptide concentration, Mw is the weight-
averaged molecular weight of particles in solution, P(90) is
the particle scattering factor at 90, Ib(90°) is the scattered
intensity of the buffer, and K is an instrument-dependent
constant,
K	
42nb2dndc
2
NAo4
Itol
Rtol
ntol
nb
(2)
where nb and ntol are the refractive indices of buffer and
toluene, respectively, dn/dc is the refractive index increment
(0.145 ml/g), NA is Avogadro’s number, 0 is the laser
wavelength in vacuo, Itol is the scattered intensity from a
toluene sample, and Rtol is the Rayleigh ratio for toluene.
Results from SEC and light scattering measurements
were combined to evaluate the average linear density lin
(mass per unit length, Magg/Lc) of the linear aggregates as
follows. If only monomer, dimer, and large aggregates are
present, then Mw  ¥wiMi  waggMagg, with Mw related
to Is(90°) per Eq. 1 and wagg given in Table 1. The fibril
contour length Lc was calculated from the measured dsph
along with an experimental estimate of fibril flexibility
(Kuhn statistical length lk  180 nm, Murphy and Pallitto,
2000), using relations derived by Yamakawa and Fujii
(1973). P(90) was calculated from Lc and lk, using the
theory derived by Koyama (1973) and described in Shen et
al. (1994). Then,
lin	
Magg
Lc
	 Is90 Ib90KctotP90  1wagg 1Lc (3)
lin, a measure of the thickness of the chains, is shown in
Fig. 4. At 70 M, lin was nearly constant over time with an
initial value of4 kDa/nm. At 140 M, lin was higher than
at 70 M (13 kDa/nm) initially, and increased modestly
over time. The most dramatic changes were observed at the
highest concentration, 280 M; lin was greater than the
other concentrations initially (20 kDa/nm), and increased
rapidly over the first8 h, then leveled out after20 hours
at 60 kDa/nm.
Aggregate hydrophobicity
The fluorescent dye bis-ANS was used as a qualitative
probe for exposed hydrophobic surfaces on A aggregates.
The dye binds to exposed hydrophobic patches on partially
folded proteins, leading to an increase in fluorescence in-
tensity and blue-shifting of the emission maximum (Gib-
bons and Horowitz, 1995). Freshly-diluted monomeric A
does not cause bis-ANS fluorescence (Kremer et al., 2000).
A was aggregated at 70, 140, or 280 M, then diluted to
2 M into a solution containing bis-ANS. In Fig. 5 A
Bis-ANS fluorescence is shown as a function of the con-
centration at which A was aggregated. At 70 M a fluo-
rescence peak was observed, which did not change appre-
ciably with time (data not shown). At 140 M, the peak
fluorescence is 2–3-fold higher, and at 280 M, the
fluorescence increased another 3–4-fold and is slightly
FIGURE 4 Linear density lin as a function of time and concentration for
70 M (E), 140 M (), and 280 M (‚). lin was calculated from dsph
and Is(90°) as described in the text.
FIGURE 5 Bis-ANS fluorescence spectra in the presence of 2 M A.
A samples were prepared at 70, 140, or 280 M as described above, then
diluted at the indicated time into a solution containing 20 M bis-ANS.
Excitation wavelength was 360 nm and a background spectrum was sub-
tracted. Binding of bis-ANS to hydrophobic sites produces an increase in
fluorescence intensity and a blue-shifting of the emission maximum to
480–490 nm. (A) Sample aggregated at 70 M (E), 140 M (), and
280 M (‚), then diluted to 2 M, taken 4 h after sample preparation. (B)
Sample aggregated at 280 M (‚), then diluted to 2 M, taken 1 h (short
dashed line), 4 h (solid line), or 2 days (long dashed line) after sample
preparation.
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blue-shifted. At 280 M (Fig. 5 B) and, to a lesser extent, at
140 M (not shown), fluorescence intensity increased over
the first few hours, then stabilized. These data suggest that
there are distinct structural differences between the aggre-
gates formed at these different concentrations.
MATHEMATICAL MODEL
Experimental results described above lay the foundation for
developing a mathematical model of A self-association ki-
netics. The key observations that the model must capture are:
1. A substantial amount of material remained in a nonfi-
brillar state, as monomers and dimers, after renaturation.
Dimer-monomer concentrations were related by a sec-
ond-order function;
2. High-molecular-weight species formed very rapidly
upon dilution;
3. The initial aggregate size was greatest at the lowest test
concentration;
4. The rate of growth increased with concentration;
5. The linear density of aggregates increased at higher
concentrations with time, eventually reaching a steady-
state value;
6. Aggregates formed at different concentrations are struc-
turally distinct, specifically in terms of exposed hydro-
phobic regions.
The development of the structure of the model will be
discussed first, followed by a description of the detailed
equations derived to solve the model.
Monomer, dimer, and aggregate
mass distribution
We observed that 1) monomer and dimer concentrations
depended on total A concentration; 2) monomer, dimer,
and aggregate distribution was relatively constant with time;
and 3) large aggregates appeared very quickly upon dilution
into PBSA. We used these data to postulate that “refolding”
of A from the urea-denatured state occurs extremely rap-
idly, and that refolded species become quickly and irrevers-
ibly committed to either monomer/dimer (nonamyloid) or
aggregate (amyloid) status. A division between amyloido-
genic and nonamyloidogenic populations of A has previ-
ously been postulated by Soto and Castano (1996), and is
conceptually similar to the division between aggregated and
correctly folded proteins observed in other protein refolding
studies (Goldberg et al., 1991). We also observed that
monomer and dimer concentrations were related by a simple
second-order equation, and therefore propose that monomer
and dimer are in rapid reversible equilibrium. Schematically
this is shown in Fig. 6 under the “refolding” step, where
Munfold represents monomeric A in its urea-denatured
state, M and D are monomer and dimer “native” conforma-
tions that are stable in PBSA, respectively, and I is an
unstable intermediate that can form larger aggregates. In the
refolding literatureM and D formation would be considered
“on-pathway” and I 3 aggregate would be “off-pathway.”
The split between amyloidogenic and nonamyloidogenic
populations was assumed to be irreversible.
We considered, and discarded, several alternative
schemes in which monomers (and/or dimers) were assumed
to be all “off-pathway”, e.g.,M3 D3 I3 aggregates. For
example, conversion to aggregates could occur via cooper-
ative association of monomer (or dimer) to reactive inter-
mediate. This model is similar to that proposed by Jarrett et
al. (1993) and Lomakin et al. (1996, 1997). Under this
model, [I] remains very small until the “critical concentra-
tion” of [M] is reached, then [M] remains constant (and
equal to this critical concentration) as total A concentra-
tion is increased. We instead observed an increase in [M]
and [D] as the total concentration increased, directly con-
tradicting this model. Two other models, used commonly to
describe linear polymerization processes (Billmeyer, 1971;
Schmidt, 1998), were explored. A association was postu-
lated to occur either via a stepwise (condensation) polymer-
FIGURE 6 Schematic of model describing kinetics of A fibril growth.
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ization scheme, in which any two oligomeric species react
to form longer polymers, or via addition (chain) polymer-
ization, in which a highly reactive initiator is formed and
monomers quickly add to the growing chain. With stepwise
polymerization, the molecular weight distribution is very
broad, and very few monomers are present for even modest
degrees of aggregation. This model is inconsistent with
experimental data. Chain polymerization produces a distri-
bution that includes only monomer and high-molecular-
weight polymer, which is closer to the observed distribu-
tion. However, the monomer concentration tends toward a
constant value, independent of total concentration, in con-
trast to observation. Several variants of these ideas were
evaluated; none were fully consistent with experimental
data. Therefore, we conclude that formation of nonamyloid
and amyloid A species occurs in parallel, not serial, fashion.
Aggregate size and shape
Two key structural features that have been consistently
observed in AFM studies are “filaments” of 3–4-nm thick-
ness and “fibrils” of 8–12-nm thickness (Stine et al., 1996;
Harper et al., 1997, 1999). Cross-section EM images and
x-ray diffraction studies indicate that fibrils contain three to
six laterally associated filaments (Fraser et al., 1991; Ma-
linchik et al., 1998). Analysis of the light scattering data
revealed increases in lin with concentration and with time,
and substantially greater (3-fold) steady-state lin at 280
M relative to initial values. Given these data and the
aforementioned EM, AFM, and XRD studies, we incorpo-
rated into our model two possible long linear aggregated
structures: filaments (thin) and fibrils (thick).
Development of the detailed kinetic model for filament
and fibril formation and elongation relied on several key
experimental observations. First, we observed that even at
the earliest time points high-molecular-weight aggregates
were present, and that the initial size (dsph) was greatest at
the lowest concentration. We postulated that this could
occur due to a nucleation-dependent process akin to crys-
tallization, where fewer longer crystals are observed at
lower concentrations and more, shorter crystals are ob-
served at higher concentrations (Jarrett et al., 1993). Thus, a
nucleation mechanism was applied not to the initial parti-
tioning betweenM/D and I, but to further self-association of
I into larger species. A high-order, cooperative reaction is
necessary to capture the inverse relationship between initial
size and concentration. We modeled filament initiation as
reversible self-association of I to form a nucleus, N, con-
taining n I, characterized by forward and reverse rate con-
stants kN and kN, respectively. This step is illustrated in
Fig. 6 as filament initiation. We further assumed that nuclei
N could elongate into filaments f by addition of I. This is
illustrated in Figure 6 as filament elongation by I addition.
The second key observation was the significant increase
in lin at 280 M with time, whereas at 70 M lin was
constant and small. We postulated that the increase in lin at
280 M was due to lateral aggregation of several filaments
into fibrils. This would be consistent with observations indi-
cating that fibrils are close-packed filaments (Fraser et al.,
1991; Malinchik et al., 1998) and would have a high reaction
order, to explain the strong concentration dependence. There-
fore filaments f were assumed to laterally associate into fibrils
F, as shown in Fig. 6. Lateral association was assumed to be
irreversible, characterized by a rate constant kla.
Third, we observed an increase in dsph without a corre-
sponding increase in lin at 280 M and longer times (t 	
20 h, see Figs. 2 and 4). The increase in dsph indicates an
increase in fibril length. No change in lin implies a constant
fibril diameter. We postulated that the increase in dsph at t	
20 h was due to axial elongation by end-to-end associa-
tion of shorter fibrils. Additional experimental evidence of
this was presented in Murphy and Pallitto (2000) and
Harper et al. (1999). End-to-end association was assumed to
be slow and diffusion-limited and was modeled after the
classic Smoluchowski equation. The rate constant associ-
ated with end-to-end association, kij, was assumed to depend
on length as (Hill, 1983, Tomski and Murphy, 1992):
kij	
kBT
3
NA
1000
22
Li
 Lj lnLi/d
 viLi 
 lnLj/d
 vjLj 
vi	 0.312
 0.565Li/d1 0.100Li/d2, (4)
where i and j indicate the size of associating fibrils, kB is the
Boltzmann constant, T is the absolute temperature,  is the
solvent viscosity,  is the maximum allowable distance
between two fibril ends,  is the maximum allowable angle
between two fibrils, Li is the fibril (or filament) length, and
d is the fibril (or filament) diameter. For completeness, a
similar mechanism for end-to-end association of filaments
was included. End-to-end association was assumed to be an
irreversible process.
Model equations
The schematic depicted in Fig. 6 and justified in detail in the
previous sections was used to derive a set of equations
describing the kinetics of A aggregation. Refolding of
denatured peptide to produce M, D, and I was described by
simple irreversible kinetic expressions:
dM
dt 	 kMMu (5)
dD
dt 	 kDMu
2 (6)
dI
dt 	 kIMu
2, (7)
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where [Mu] is the concentration of monomer in the urea-
unfolded state. The initial distribution among M, D, and I
was assumed to occur very rapidly, relative to further I
association. The data were best modeled if I was assumed to
be dimeric, hence the form of Eq. 7. Equations 5–7 were
solved to give a pseudo-steady-state expression for [I], i.e.,
the value that would be obtained at long times if there were
no further aggregation of I:
I	 2 kIkI
 kDMu02  kM4kI
 kD
 ln1
 2kI
 kDMu0kM  , (8)
where [Mu]0 is the initial A concentration in the unfolded
state. The amount of M and D formed is simply:
M
 D	 Mu0 I (9)
We assumed that “native” monomer M and dimer D were
always in equilibrium:
Kmd	
D
M2 (10)
Equations 8–10 give the initial concentrations of M, D, and
I just after dilution into PBSA. For convenience, M, D, and
I concentrations are given in equivalent monomer molar
concentrations.
I is consumed by initiation and elongation steps (Fig. 6)
and associates to form N, or adds to N to form filaments, or
adds to filaments to increase their length. The shortest
filament is produced by addition of I to N and is referred to
as fn1. Filaments can be any size i from (n 1) to , where
n is the number of I per N. (There are 2i monomers per
filament fi.) Summing over all species gives:
dN
dt 	 knI]
n knN kpI][N
 kpfn1 (11)
dI
dt 	nknI
n
 nknN
 kpIN
 
in1

fi 
 kp 
in1

fi  (12)
A filament of length i, fi, is formed by addition of I to fi1
or by end-to-end association of two shorter filaments (fj and
fk, where j  k  i); fi is lost by similar reactions: addition
of I to form fi1, or end-to-end association with any filament
fj to form filaments of length i j. In addition, filaments are
lost by (irreversible) lateral aggregation to fibrils. Mathe-
matically, this is expressed as:
dfi
dt 	 kpIfi1 fi
 kpfi fi1 pklafi 
jn1

fjq1
 
jn1

kijfifj

1
2 jn1
i(n1)
kj,ijfjfij (13)
where p is the number of filaments per fibril, q is the order
of the lateral association reaction, kla is the lateral associa-
tion rate constant (assumed independent of length), and kij
and kjk are end-to-end association rate constants for fila-
ments (defined in Eq. 5). Since i varies from n  1 to ,
there are an infinite number of equations like Eq. 13. To
make this system of equations finite, we defined moments
of the filament size distribution f:
f 	 
in1

ifi (14)
Fibrils form by lateral association of filaments and grow in
length by end-to-end association of shorter fibrils. We de-
fined moments of the fibril size distribution F:
F 	 
in1

iFi, (15)
and assumed that the length of fibrils formed by lateral
association was equal to the number-average length of fil-
aments at that time. Substituting in the definition of mo-
ments (Eqs. 14 and 15) into Eqs. 12 and 13, and similarly
deriving equations for fibril formation and growth, produces
a finite set of coupled differential equations:
dI
dt 	nknI]
n nknN kpI]{[N
 f0
 kpf0
(16)
df0
dt 	 kpNI kpfn1 pklaf0
q 
1
2 kijf0
2 (17)
df1
dt 	 kpIn
 1N
 f0
 kpnfn1
 f0 pklaf1f0q1 (18)
df2
dt 	 kpIn
 1
2N
 2f1
 f0
 kpn2fn1
 f0 f1
 pklaf2f0q1
 kijf12 (19)
dF0
dt 	 klaf0
q 
1
2 kijF0
2 (20)
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dF1
dt 	 pklaf1f0
q1 (21)
dF2
dt 	 p
2klaf2f0q1
 kijF12 , (22)
where kij are kij were calculated from Eq. 4 using the
number average length of filaments or fibrils, respectively.
Parameter estimation procedure
Equations 16–22 together with Eq. 11 were solved numer-
ically using the program DDASAC (Caracotsios and Stew-
art, 1985). Model parameters were derived by fitting exper-
imental data to model equations, using the parameter
estimation package GREG (Stewart, 1987) and the follow-
ing procedure.
First, we determined the “refolding” parameters. Estimates
of Kmd  0.64 
 0.08 M1, kM/kI  80 
 30 M, and
kD/kI  0.65
 0.15 were obtained by nonlinear regression fit
of the data in Table 1 to Eqs. 8–10. Because these are rapid
reactions, only the ratios of rate constants, rather than the
absolute values, could be evaluated. As shown in Fig. 7, the
model calculations accurately reflect the observed population
distribution at all three concentrations tested. We considered
and discarded mechanisms in which kM or kD was set equal to
zero, because these were not able to capture the observed
trends satisfactorily (not shown). Addition of the extra param-
eter is statistically justified at the 99.5% level, using the F-
statistic (Davies, 1954).
Second, we determined the parameters involved in fila-
ment initiation and elongation. To compare experimental
data to model simulations, a method was developed that
relates the experimental observations dsph and Is(90) to the
size distributions calculated from the model. The weight-
average-molecular-weight of filaments Mf and fibrils MF
were related to model-generated distributions as:
Mf	 2M1
f2
f1
MF	 2M1
F2
F1
(23)
where M1 is the monomer molecular weight. Filament and
fibril lengths were calculated assuming a solid cylindrical
geometry:
Lf	
4vhMf
df2NA
LF	
4vh
df2NA
MF
p , (24)
where the hydrated specific volume vh was set equal to 1.1
cm3/g (Tomski and Murphy, 1992), and the filament diam-
eter df was set equal to 4 nm (Harper et al., 1999). dsph,f and
dsph,F were calculated from Lf and LF, respectively, as de-
scribed in Shen et al. (1994). The inverse z-averaged dsph
was then calculated from:
dsph	 wfMfdsph,f1
 wFMFdsph,F1wfMf
 wFMF 
1
(25)
FIGURE 7 Observed (dark shading) and simulated (lightly shaded)
weight fraction of (A) monomer, (B) dimer, and (C) aggregate. Samples
were prepared at the indicated total A concentration; distributions were
evaluated from size exclusion chromatograms. Concentrations are given as
equivalent monomer concentrations.
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where wf and wF are the weight fractions of filament and
fibril, respectively, calculated from the model. In sum, Eqs.
23–25 allow a direct comparison between experimentally
obtainable values and model calculations of dsph.
Is(90°) was related to the distribution as follows. The
weight-average molecular weight Mw of the entire sample
was determined from:
Mw	
M
 4D
 n2N
 f2
 F2
M
 2D
 nN
 f1
 F1
M1 (26)
Lf and LF were used to calculate the particle scattering
factors, Pf(90°) and PF(90°), for filaments and fibrils, re-
spectively (Koyama, 1973; Shen et al., 1994), assuming
lk  180 nm for both filaments and fibrils (Murphy and
Pallitto, 2000). The overall scattering factor P(90) was
determined by averaging the individual values (Burchard,
1983):
P90	
wfMfPf90
 wFMFPF90
wfMf
 wFMF
. (27)
The scattered intensity was calculated from Eqs. 9, 26, and
27. Together, Eqs. 24, 26, and 27 relate experimentally
observable values of Is(90°) to size distributions calculated
from the model.
As previously discussed, at 70 M the values of dsph and
Is(90°) indicated large aggregates were present very soon
after dilution into folding buffer. Furthermore, dsph and
Is(90°) at 70 M did not change with time. We interpreted
this to indicate 1) that filament initiation and filament elon-
gation by I addition was rapid, and 2) that slower growth by
end-to-end association or lateral association was negligible
at this concentration. Given this, initial estimates of param-
eter values were obtained from the experimental data at 70
M by setting all parameters except kn, kp, and n equal to
zero and by neglecting time-dependent terms in Eqs. 11 and
16–22. These simplified equations together with Eqs. 23–25
give dsph as a function of the ratio kn/kp and n. We fixed n,
and found the best-fit value for kn/kp by comparing observed
and calculated values for initial dsph. This procedure was
repeated for varying choices of n. Then, these sets of (n,
kn/kp) were used along with the model equations to calculate
the initial dsph at the two higher concentrations. Closest
agreement with all three concentrations was obtained with
n  6 and kn/kp  1.7  106 M4. This result indicates
that 6 I cooperatively associate to form N, with a sixth-order
dependence on concentration of I.
Lastly, we determined the parameters describing lateral
association and end-to-end axial elongation. For this, kn
and kp were kept close to zero. This is equivalent to
assuming that filament initiation and elongation are essen-
tially irreversible; subsequent calculations indicated that
small changes in the chosen rate constants did not change
the model output (not shown) and that no unique values for
these reverse rate constants could be ascertained from the
data. Three kinetic rate constants, kij, kij, kla, plus p and q
remained to be determined. We fixed p and q arbitrarily to
different integer values between 2 and 6, based on reports
that fibrils contained three to six subunits (Fraser et al.,
1991; Malinchik et al., 1998), then fitted kinetic rate con-
stants at given values of p and q by weighted multi-param-
eter nonlinear regression to the dsph and Is(90°) data at both
140 and 280 M. The “best” parameter set was chosen as
that which gave the lowest sum of squares of the residuals.
The data were best fit by a model wherein fibrils were
composed of six laterally associated filaments. The chosen
model parameters are summarized in Table 2.
Model simulations and evaluation
Fibril growth at 70, 140, and 280 M A was simulated
using the model and the parameter set given in Table 2. The
data and simulations are shown in Fig. 8. The model does
very well in accurately simulating the increase in dsph with
time at all three concentrations (Fig. 8, A and B). The model
captures the shape of Is(90°) data versus time quite well
(Fig. 8, C and D), but misses slightly in absolute terms at 70
M (all times) and at 280 M (long times). Is(90°) values
are very sensitive to total peptide concentration, and the
relationship between dsph and Is(90°) is very sensitive to the
assumed filament diameter. A small error in either would
lead to a relatively large error in the absolute value of
Is(90°), which likely explains the differences between
model and data at 70 M. An additional complication arises
due to the manner in which fibril length was calculated. To
calculate the relationship between MF and LF, we assumed
that the effective cross-sectional area was  p df2, where df
is filament length (Eq. 24). A different relationship would
be obtained if we used  dF2, where dF is the fibril diameter.
Physically, this could be explained as twisting and coiling of
the fibril after filament lateral association; however, we had
no direct means to quantify this phenomenon. Such com-
paction of fibrils would change the relationship between
dsph and Is(90°) in the case where fibrils are a significant
fraction of the aggregated material, and thus may explain
TABLE 2 Model parameters
Parameter Value
KMD 0.64 
 0.08 M1
kM/kI 80 
 30 M
kD/kI 0.65 
 0.15
kn/kp 1.7 
 0.1  106 M4
kla 4.7 
 0.3  103 M2 h1
fil 9.8 
 0.9  1010 cm-rad
fib 1.06 
 0.03  108 cm-rad
n 6
p 6
q 3
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the discrepancy between simulation and data at longer times
with 280 M.
Next, we used the model to gain insight into growth
patterns for filaments and fibrils, information that is difficult
to access directly by experiment. The parameters given in
Table 2 were used, and simulations were run at 70, 140, and
280 M. In Fig. 9, we plot the weight fraction of A in
filament and fibril form, and the filament and fibril length,
as a function of time and concentration. At 70 M, virtually
all the aggregated peptide exists as filaments. As concen-
tration increases, the distribution shifts toward fibrils, and
the time frame over which fibrils form decreases (Fig. 9, A
and B). Qualitatively, these simulations are in agreement
with bis-ANS data, if we assume that filaments bind less of
the fluorescent dye than do fibrils. Filaments at 70 M are
much longer than those found at the higher concentrations
(Fig. 9 C), and initial filament size decreases with increas-
ing concentration. This pattern is due to the competition
between nucleus formation and filament elongation, both of
which consume I. Over longer time, filament size tends to
the same value, 200 nm, at both 140 and 280 M. Fibrils
are only slightly longer than filaments at 140 M, whereas
at 280 M fibrils grow considerably longer, indicating that
fibril elongation becomes a dominant growth mechanism
only at higher concentrations.
We simulated the behavior at A concentrations below 70
M (Fig. 10). Interestingly, the concentration of I becomes
measurable only at10 M total A and reaches a maximum
at25 M total A. Below this point, less unfolded monomer
is converted to I and the concentration of I is insufficient to
drive significant further aggregation. Above this point, further
association into N, filaments, and fibrils is favored. This gives
an overall “critical concentration” for high-molecular-weight
aggregates of 20 M. These predicted values are very close
to experimental values reported by others (Soreghan et al.,
1994; Huang et al., 2000).
We examined the necessity of including filament and
fibril elongation and lateral association in our model. We
refit the data with one kinetic parameter (fil, fib, or kla)
set equal to zero. The model was unable to converge without
the fibril elongation step, justifying inclusion of fibril elon-
gation as a necessary growth mechanism. Without lateral
association, model simulations were unable to capture the
experimental data at the two higher concentrations (not
shown). Excluding filament elongation (fib  0) was less
problematic; the observed plateau for Is(90°) at 280 M is
more closely approached, but at the expense of capturing the
rate of increase in Is(90°) at early times (not shown). Thus,
filament elongation makes a minor, almost negligible, con-
tribution to the aggregation pathway. Interestingly, in AFM
FIGURE 8 Measured average hydrodynamic diameter dsph and average scattered intensity Is(90°) of A aggregates at 70 M (E), 140 M (), and 280
M (‚) are shown along with model simulations (lines) generated using parameters given in Table 2.
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studies Harper et al. (1999) suggested that filament elonga-
tion was much slower than fibril elongation.
Relationship of A aggregation state to
A toxicity
To examine whether our kinetic model could provide in-
sight into mechanisms of A toxicity, we prepared A
solutions by urea denaturation followed by dilution into
PBSA at 70, 140, and 280 M. Samples were aggregated
for 1 or 3 days at room temperature, then applied to plated
PC-12 cells at a constant final A concentration of 35 M.
Cell toxicity was ascertained by MTT reduction assay after
24 h exposure. As shown in Fig. 11, toxicity decreased with
increasing aggregation concentration and, to a lesser extent,
increasing aggregation time. We used the model to simulate
A aggregation at the three different concentrations, and
compared simulations to toxicity data. The strongest corre-
lation was observed between cell toxicity and fraction of
aggregated A present as filaments (Fig. 11). At 70 M, as
shown in more detail in Fig. 9, 30% of A was aggre-
gated, and virtually all the aggregated peptide was present
as filaments; this sample was extremely toxic, with cell
viability only3% of control (untreated) wells. At 280 M,
nearly 50% of the A was aggregated, but much of this
(75–80%) was fibrils. This sample was much less toxic to
the cells. This correlation suggests that the filament form of
A is the toxic species.
DISCUSSION
Deposition of A as insoluble fibrillar aggregates is one of
the defining pathological features of Alzheimer’s disease,
and a number of epidemiological, genetic-linkage, and
transgenic mouse studies indicate that A deposition is
causally linked to neurodegeneration. Early in vitro studies
indicated the requirement of aggregation for A toxicity
(Pike et al., 1993; Simmons et al., 1994; Lorenzo and
Yankner, 1994; Seilheimer et al., 1997). In more recent
years an alternative hypothesis has gained exposure, namely
that a soluble intermediate in the fibrillogenesis pathway,
not the final insoluble product, is the toxic moiety (Pallitto
et al., 1999; Lansbury, 1999; Koo et al., 1999). As exam-
ples, dimeric (Roher et al., 1996), oligomeric (Lambert et
al., 1998), and “protofibrillar” A (Hartley et al., 1999;
Ward et al., 2000) are reportedly toxic to cultured cells.
Additionally, A fibrils pre-deposited onto a solid surface
were not toxic to neurons, even though solutions of A
fibrils were toxic (Wujek et al., 1996).
FIGURE 9 Model simulations using parameters given in Table 2. (A) Weight fraction of total A present as filaments, (B) weight fraction of total A
present as fibrils, (C) average filament length, and (D) average fibril length for 70 M (E), 140 M (), and 280 M (‚).
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Given the biological relevance of A fibrillogenesis, the
pathway and kinetics by which A monomers form fibrils
have been the subject of investigation (see Murphy and
Pallitto, 2000, for brief review). Jarrett et al. (1993) pro-
posed a qualitative kinetic model for A self-association
which included a lag phase, a rapid growth phase, and then
a plateau phase. Tomski and Murphy (1992) derived a
quantitative model that described the kinetics of fibril elon-
gation. Naiki and Nakakuki (1996) proposed that fibrils
elongated by reversible addition of monomer to preexisting
fibrils and derived a simple mathematical model. Lomakin
et al. (1996, 1997) published the most detailed mathematical
model to date. Briefly, monomers were postulated to rapidly
and reversibly form micelles from which nuclei slowly but
irreversibly emerged; fibrils elongated by addition of mono-
mer to nuclei or other fibrils. This model accounts for the
presence of both monomer and fibrillar forms, and can
predict both the mass concentration of fibrils and fibril
length as a function of time. However, the experiments upon
which the model was based were conducted at nonphysi-
ological conditions (pH  1). None of the published kinetic
models distinguishes between filaments and fibrils, or ac-
counts for conversion between these two states. Yet, based
on atomic force microscopy observation, Harper et al.
(1999) suggested that lateral aggregation of filaments into
fibrils is a key, perhaps rate-limiting, step in the assembly
process.
In this work we developed a comprehensive mathemati-
cal model of the kinetics of A aggregation that is consis-
tent with numerous experimental observations. This model
is a significant improvement over previous mathematical
models for several reasons: 1) experiments were performed
at physiological pH, 2) initiation and growth mechanisms
were included, 3) both monomer addition and fibril-fibril
association were included as growth mechanisms, 4) both
filaments and fibrils were included, and 5) mass fractions
and filament/fibril lengths are modeled.
A key feature of our model is the hypothesis that un-
folded A, upon dilution into a “folding” buffer, rapidly and
irreversibly partitions between two pathways. One pathway
produces monomers and dimers of stable (but undefined)
structure. Indeed, recent studies suggest that at low concen-
trations (20 M), A forms a mix of monomers, dimers,
and tetramers lacking regular secondary structural features
(Huang et al., 2000). The other pathway generates an un-
FIGURE 10 Model simulations at low concentrations, using parameters
given in Table 2. (A) Concentration of I (solid line) and of amyloidogenic
A (I  N  filaments  fibrils, dashed line), in equivalent monomer
concentration, as a function of total A concentration. (B) Weight fraction
of aggregates (filaments  fibrils) as a function of total A concentration.
FIGURE 11 (A) Cell viability for A-treated PC-12 cells, assessed using
the MTT assay. A was solubilized in 8 M urea, pH 10, diluted into PBSA,
aggregated at the indicated concentration and time, then diluted to 35 M
and added to plated PC-12 cells. (B) Wt % aggregated A in filament form,
calculated from the kinetic model at the indicated concentration and time.
1818 Pallitto and Murphy
Biophysical Journal 81(3) 1805–1822
stable intermediate that aggregates further. A species in
this branch are likely -sheet-containing oligomers (Barrow
et al., 1992). Our simulations predict a narrow concentration
range over which a -sheet dimeric intermediate would
exist in the absence of significant highly aggregated species.
Partitioning between a non-amyloidogenic (“on”) pathway
and an amyloidogenic (“off”) pathway is a unique feature of
our mathematical model, although experimental evidence
for such a partitioning has been presented previously (Soto
and Castano, 1996). Similarly, amyloid fibril formation
from transthyretin is believed to proceed via formation of an
alternatively folded conformation that is -sheet rich
(Lashuel et al., 1999). This result suggests that there is a
normal “folded” A structure; possibly, this stable structure
has a normal physiological function. Using our model, we
calculate that at 10 nM A, 	99% of the peptide is stable
monomer, while at 10 M A, 10% of the peptide is in
the “amyloidogenic” pathway.
A second unique feature of our mathematical model is the
explicit inclusion of both filaments and fibrils as distinct
aggregated forms of A. Several investigators have ob-
served both filaments (linear aggregates of 3–4 nm diam-
eter) and fibrils (linear aggregates of 8–12 nm diameter)
using electron microscopy, atomic force microscopy, and
x-ray diffraction (e.g., Fraser et al., 1991; Harper et al.,
1997, 1999; Malinchik et al., 1998). Our model is consistent
with these structural observations. Furthermore, the number
of filaments per fibril extracted from our model fit (p  6)
is consistent with experimental observations (Fraser et al.,
1991; Malinchik et al., 1998).
Conversion of unstable intermediate to larger aggregates
is proposed to proceed via four steps: initiation via cooper-
ative association of intermediate, elongation by addition of
monomer to filament, lateral aggregation of filament to
fibril, and elongation by end-to-end association of shorter
fibrils or filaments. All four of these steps are consistent
with our experimental evidence and that obtained by AFM
(Harper et al., 1999). Both the initial size of aggregates and
the rate of growth are highly concentration-dependent. This
is evidence of the highly cooperative nature of A fibril
formation and growth. Our data were best fit by a sixth-
order reaction for conversion of intermediate to nucleus
(fibril initiation) and a third-order reaction for conversion of
filaments to fibrils (lateral aggregation). The two mecha-
nisms for elongation, monomer addition and end-to-end
association of smaller fibrils, are both second-order reac-
tions. Thus, at lower concentrations, elongation is relatively
more important and a few long filaments are produced,
whereas at higher concentrations, initiation and lateral ag-
gregation become more dominant features.
The model specifically applies to the situation where A
starts in the urea-denatured state. We chose this to ensure
that the initial state of A was defined as fully monomeric
and unfolded. The model could easily be adapted to simu-
late alternative initial conditions. The secondary structure
and state of aggregation of A is a strong function of the
solvent in which it is dissolved (Barrow et al., 1992; Shen
and Murphy, 1995; Thunecke et al., 1998). We suspect that
the fraction of material committed to the “on” versus the
“off” pathway is very sensitive to the manner in which it is
treated, i.e., the peptide’s history. This affects the initial
distribution of monomeric, dimeric, intermediate, and other
species. This, coupled with the strong concentration depen-
dence, may explain the markedly different results obtained
by using different solvents for dissolution, and the batch-
to-batch and lab-to-lab variability reported by investigators
of A aggregation. Residual urea in the final solution could
affect A conformation or aggregation kinetics, perhaps by
binding to the surface of aggregated peptide. We have
previously published data on kinetics of A growth from
the DMSO-denatured state (Kremer et al., 2000). Prelimi-
nary analysis of the data in light of our mathematical model
suggests that the split between the “on” and “off” pathways,
and kn/kp, are not significantly affected by the change from
DMSO to urea, but kla is greater. We speculate that this
indicates that residual urea inhibits lateral aggregation of
filaments into fibrils; more detailed analysis and experimen-
tation is underway.
As with any model, some simplifications were needed
that may limit the range over which extrapolations are
feasible. In particular, we assumed several reactions were
irreversible, or nearly so. There are no mathematical diffi-
culties that prevent incorporation of reversible reactions into
the model; what is missing are experimental data that allow
values for these parameters to be uniquely fit. Another
limitation is that the model (and the experimental data from
which it was derived) is restricted to a single phase. A
further refinement of the model would include heteroge-
neous association between A in solution and A deposited
as a solid phase. There is clear evidence that such associa-
tion exists and is likely an important mechanism for growth
of amyloid deposits in vivo (Tseng et al., 1999; Esler et al.,
2000).
The nonlinear nature of the system (high reaction order,
and participation of species in multiple steps) means that it
is difficult, if not impossible, to characterize or predict A
aggregation kinetics without a mathematical model. Simu-
lations can provide insights into experimentally inaccessible
time frames or concentrations. For example, most biophys-
ical studies of A kinetics are conducted with concentra-
tions in the M range, on a time scale of minutes to days,
whereas the concentration of soluble A in cerebrospinal
fluid is nanomolar, with aggregation and deposition taking
place over years. Extrapolation of a model derived from
data taken under experimentally accessible conditions to
physiologically relevant conditions is hazardous, yet may be
the only reasonable way to mimic the in vivo situation. The
model can easily be modified to simulate other conditions of
interest (e.g., addition of preformed fibrils to A mono-
mers.)
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Quantitative kinetic models such as the one developed
here can serve as useful tools to validate or refute hypoth-
eses regarding the mechanism of toxicity of A. In our
experiments, toxicity was strongly dependent on the aggre-
gation concentration, even though the final A concentra-
tion to which cells were exposed was identical. Based on
our model simulations, we speculate that long soluble fila-
ments are the predominant toxic species. Other published
results are consistent with our findings. Wujek et al. (1996)
reported that fibril solutions, not fibrillar deposits, were
toxic. Ward et al. (2000) fractionated aged A and reported
that toxicity was restricted to fractions containing “protofi-
brils” (rod-like structures 3–4 nm in diameter) and mature
fibrils (longer branched fibrillar structures 6–12 nm in
diameter). Interestingly, the protofibril-enriched fractions
were toxic at much lower (equivalent monomer) concentra-
tions than the mature fibrils. We have previously demon-
strated that peptidyl inhibitors that increase A aggregation
kinetics and decrease time to formation of precipitates also
protect cells from A toxicity (Ghanta et al., 1996; Pallitto
et al., 1999; Lowe et al., 2001). We speculate that such
inhibitors accelerate the rate of conversion of filaments to
fibrils and fibrillar deposits.
Many natural and synthetic compounds have been sus-
pected of enhancing or inhibiting A aggregation. This
list includes: glycosaminoglycans (McLaurin et al.,
1999), 2-macroglobulin (Hughes et al., 1998), high den-
sity lipoprotein (Olesen and Dago, 2000), apolipoprotein
E (Ma et al., 1994), Beffert and Poirier, 1998); ganglio-
sides (Choo-Smith and Surewicz, 1997), metal ions
(Bush et al., 1994), tetracyclic compounds (Howlett et
al., 1999), pyridones (Kuner et al., 2000), peptides
(Ghanta et al., 1996; Soto et al., 1996; Tjernberg et al.,
1997; Findeis et al., 1999), and detergents (Wood et al.,
1996). Compounds could variously prevent, slow, or accelerate
the rates of nucleation, lateral association, or elongation, or
could change partitioning between amyloidogenic and non-
amyloidogenic pathways. The mode of action can be iden-
tified by combining our kinetic model with appropriate
experimental data. Such analysis would be beneficial in
identifying compounds that increase or inhibit the propen-
sity of A to form toxic aggregated species. Additionally,
identification of the key steps involved in regulating the
distribution of A species should aid in developing novel
compounds of therapeutic value.
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